Novel (1,2,4)triazolo(1,5-a)pyridylphosphorus oxide and its use
By developing new [1,2,4]triazolo[1,5-a]pyridylphosphine oxide, the problem of drug resistance in EGFR mutant non-small cell lung cancer was solved, and the EGFR T790M/C797S mutation was achieved Effective inhibition of type cells demonstrates excellent inhibitory activity and tumor treatment effect.
Patent Information
- Application Number
- CN201911199979.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-01-08
- Filing Date
- 2019-11-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-11-29
AI Technical Summary
Existing EGFR kinase inhibitors have drug resistance problems in the treatment of EGFR mutant non-small cell lung cancer, especially the drug resistance caused by T790M and C797S mutations is difficult to effectively resolve. The existing drugs have limited inhibitory effect on these mutant cells.
A novel [1,2,4]triazolo[1,5-a]pyridylphosphorus oxide was developed as an inhibitor of EGFR T790M/C797S mutant kinase, used as a new therapeutic agent, through the synthesis of a variety of The compound was tested for cell activity to determine its IC50 value and inhibitory activity.
This compound showed excellent inhibitory effect on cells with abnormal expression of EGFR T790M/C797S. The IC50 value reached nM level and had excellent inhibitory activity of EGFR T790M/C797S. It can effectively inhibit the proliferation of tumor cells and show good results in animals. Tumor suppression effect.
Smart Images

Figure CN111410667B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to novel (1,2,4) triazolo(1,5-a) pyridyl phosphorus oxide and uses thereof. Background Art
[0002] In my country, patients with non-small cell lung cancer (NSCLC) account for about 85% of the total number of lung cancer cases, of which about 30%-40% will have epidermal growth factor receptor (EGFR) mutations. EGFR-TKI is the standard first-line treatment for patients with EGFR mutation NSCLC. Therefore, the development of EGFR inhibitors is a major research hotspot in the field of lung cancer treatment.
[0003] Commonly used first-generation and second-generation EGFR targeted drugs include gefitinib (Iressa), erlotinib (Tarceva), icotinib (Cimena), and afatinib (Gitere). However, most patients will develop drug resistance after using this type of targeted drug for about a year. The cause of drug resistance may be the T790M mutation of the EGFR gene (about 60%), or c-MET amplification, HER2 mutation, downstream KRAS or BRAF activation, etc., and some patients will transform into small cell lung cancer. How to solve the problem of EGFR drug resistance? The answer is that the right medicine must be used for the right disease. For example, for the T790M mutation, AstraZeneca launched the third-generation EGFR TKI targeted drug Tagrisso (osimertinib, or AZD9291). With Tagrisso's approval for marketing in China and the entry of the third-generation EGFR-TKI targeted drugs into routine clinical treatment of lung cancer, more patients with EGFR mutations have the hope of receiving treatment, but a group of lung cancer patients developed third-generation TKI resistance after taking the drug; genome sequencing found that drug resistance mainly occurred in the C797S mutation of EGFR. Therefore, existing EGFR kinase inhibitor drugs still need to be improved, and there is an urgent need to develop a new, safe and effective new generation of EGFR kinase inhibitors. Summary of the invention
[0004] The purpose of the present invention is to overcome the defects of the prior art and provide a novel (1,2,4) triazolo(1,5-a) pyridylphosphorus oxide and its use. The novel (1,2,4) triazolo(1,5-a) pyridylphosphorus oxide provided by the present invention can be used as an EGFR T790M / C797S mutant kinase inhibitor for the treatment and / or prevention of tumors.
[0005] According to the first aspect of the present invention, the present invention provides a compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof,
[0006]
[0007] in,
[0008] A is selected from C, N, O, or S;
[0009] The R1 is selected from H, C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl;
[0010] R2 is selected from H, C1-C8 alkyl, or C1-C8 heteroalkyl;
[0011] The R3 is selected from H, halogen, cyano, C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl;
[0012] The R4 is selected from C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl;
[0013] The R5 is selected from H, halogen, cyano, C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl.
[0014] Preferably, the "hetero" in "C1-C8 heteroalkyl", "C3-C8 heterocycloalkyl", "five-membered heteroaryl" or "six-membered heteroaryl" represents a heteroatom or a heteroatom group. According to an embodiment of the present invention, the heteroatom or heteroatom group is independently selected from -O-, -S-, -NH-, =O, -ON=, -C(=O)O-, -C(=O)-, -S(=O)-, -S(=O)2-, -C(=O)NH-, -S(=O)2NH-, or -NHC(=O)NH-, and in any of the above cases, the number of heteroatoms or heteroatom groups is independently selected from 1, 2 or 3.
[0015] According to an embodiment of the present invention, the compound of formula I of the present invention, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, is selected from any one of the following:
[0016]
[0017] Wherein, the definitions of R1 to R5 and A group are as described above.
[0018] Therefore, throughout this specification, those skilled in the art can select R1 to R6, A group and substituents thereof in the compound shown in Formula I to provide a stable compound shown in Formula I as described in the embodiments of the present invention, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof.
[0019] According to an embodiment of the present invention, the compound of formula I of the present invention, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, the compound of formula I is selected from any one of the following:
[0020]
[0021]
[0022] In the present invention, those skilled in the art can select the groups and substituents thereof in the compound shown in Formula I to provide a stable compound shown in Formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, including but not limited to I-1 to I-14 described in the embodiments of the present invention.
[0023] The reaction solvent used in each reaction step described in the present invention is not particularly limited, and any solvent that can dissolve the starting material to a certain extent and does not inhibit the reaction is included in the present invention. In addition, many similar modifications, equivalent replacements, or solvents, solvent combinations, and different ratios of solvent combinations that are equivalent to those described in the present invention are all considered to be included in the scope of the present invention.
[0024] According to the second aspect of the present invention, the present invention provides a pharmaceutical composition, which contains an effective dose of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, and at least one pharmaceutical excipient.
[0025] The pharmaceutical excipients can be those widely used in the field of drug production. Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition, and can also provide methods to dissolve the active ingredient at a desired rate after the subject receives the administration, or promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipients can be inert fillers, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipients can include one or more of the following excipients: adhesives, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents and sweeteners.
[0026] The pharmaceutical composition of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.
[0027] The pharmaceutical composition of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical composition of the present invention can also be a controlled release or delayed release dosage form (e.g., liposomes or microspheres). Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of preparations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.
[0028] Oral administration of the compounds of the invention is preferred. Intravenous administration of the compounds of the invention is also preferred. Other routes of administration may be applicable or even preferred, depending on the circumstances. For example, transdermal administration may be highly desirable for patients who are forgetful or irritable with oral medications. In special cases, the compounds of the invention may also be administered by transdermal, intramuscular, intranasal or rectal routes. The route of administration may vary in any manner, subject to the physical properties of the drug, the convenience of the patient and caregiver, and other relevant circumstances.
[0029] According to the third aspect of the present invention, the present invention provides the use of the compound shown in formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutical composition thereof in the preparation of a drug for treating and / or preventing a disease caused by an abnormal EGFR T790M / C797S mutation. The compound provided by the present invention can be used to treat and / or prevent one or more diseases caused by an abnormal EGFR T790M / C797S mutation, and has good clinical application and medical use.
[0030] The present invention provides a compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, or a pharmaceutical composition thereof for use in the preparation of EGFR T790M / C797S inhibitor drugs. The compound provided by the present invention has excellent EGFR T790M / C797S inhibitory activity, can be effectively used as an EGFR T790M / C797S inhibitor, and can be used as a therapeutic drug for EGFR T790M / C797S inhibitors.
[0031] According to a fifth aspect of the present invention, the present invention provides a compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, or a pharmaceutical composition thereof for use in the preparation of a drug for treating and / or preventing cancer. The compound provided by the present invention can be used to prepare a drug for treating and / or preventing cancer, wherein the cancer includes but is not limited to lung cancer, glioma, renal cancer, prostate cancer, pancreatic cancer, and breast cancer. Because various solid cancers, as long as there is an abnormal mutation of EGFR T790M / C797S, can be used to apply the patented compound.
[0032] Terms and Definitions
[0033] Unless stated otherwise, the following terms used in the specification and claims have the following meanings.
[0034] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched chain groups of 1 to 20 carbon atoms, for example, straight and branched chain groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. "Alkyl" herein can be a monovalent, divalent, or trivalent group. Non-limiting embodiments include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, and various branched chain isomers thereof. Non-limiting embodiments also include methylene, methine, ethylene, ethylene, propylene, propylene, butylene, butylene and various branched chain isomers thereof. Alkyl can be optionally substituted or unsubstituted.
[0035] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, which includes 3 to 12 ring atoms, for example, 3 to 12, 3 to 10 or 3 to 6 ring atoms, or can be a 3, 4, 5, 6-membered ring. Non-limiting examples of monocyclic cyclic radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc. The cyclic radical can be optionally substituted or unsubstituted.
[0036] "Heterocycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, which includes 3 to 20 ring atoms, for example, 3 to 16, 3 to 12, 3 to 10 or 3 to 6 ring atoms, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O) m (wherein m is 0, 1 or 2) heteroatoms, but does not include -OO-, -OS- or -SS- ring moieties, and the remaining ring atoms are carbon. Preferably 3 to 12 ring atoms are included, wherein 1-4 are heteroatoms, more preferably heterocycloalkyl rings include 3 to 10 ring atoms, most preferably 5-membered rings or 6-membered rings, wherein 1-4 are heteroatoms, more preferably 1-3 are heteroatoms, and most preferably 1-2 are heteroatoms. The non-limiting examples of monocyclic heterocyclic radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic radicals include spirocyclic, condensed rings or bridged heterocyclic radicals.
[0037] "Halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
[0038] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0039] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are independently replaced by a corresponding number of substituents.
[0040] "Pharmaceutically acceptable salts" refer to salts of compounds of the invention, prepared from compounds of the invention having specific substituents with relatively nontoxic acids or bases. When the compounds of the invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts or similar salts. When the compounds of the invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid and the like; also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain basic and acidic functional groups, and thus can be converted into either base or acid addition salts. Preferably, salt is contacted with alkali or acid in a conventional manner, and then the parent compound is separated, thus regenerating the neutral form of the compound. The difference between the parent form of the compound and the form of its various salts is that some physical properties, such as different solubility in polar solvents. According to embodiments of the present invention, preferably the pharmaceutically acceptable salt of the compound shown in Formula I of the present invention is hydrochloride, hydrobromide, phosphate or sulfate, most preferably hydrochloride.
[0041] "Pharmaceutical composition" means a mixture containing one or more compounds of Formula I described herein, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or tautomers thereof, and other chemical components, as well as other components such as pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0042] The present invention synthesizes a series of novel [1,2,4] triazolo[1,5-a] pyridylphosphine oxides. The activity tests of relevant enzymes and cells show that the compounds of the present invention have excellent cell activity, and their IC50 value for cell proliferation in vitro reaches nM level, which can be well applied in various tumors. According to the embodiments of the present invention, the compounds of the present invention have very good inhibitory effects on human non-small cell lung cancer cells BaF3 with abnormal expression of EGFR T790M / C797S. And the in vivo efficacy experiments in animals further confirm the excellent tumor inhibition effect of the compounds of the present invention. The compounds of the present invention have excellent EGFR T790M / C797S inhibitory activity, can be used as therapeutic drugs for preparing EGFR T790M / C797S inhibitors, used for treating and / or preventing one or more diseases caused by abnormal mutations of EGFR T790M / C797S, and used for preparing drugs for treating and / or preventing cancer.
[0043] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. DETAILED DESCRIPTION
[0044] The preparation of the compound shown in formula I of the present invention, or its pharmaceutically acceptable salt, or its hydrate, or its solvate, or its metabolite, or its stereoisomer, or its tautomer, or its prodrug can be completed by the exemplary method described in the following examples and the relevant public literature operation used by those skilled in the art, but these examples are not intended to limit the scope of the present invention. The present invention is described in detail below by way of examples, but it is not intended to limit any adverse restrictions on the present invention.
[0045] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR is measured using a Bruker AVANCE-400 or Varian Oxford-300 nuclear magnetic spectrometer, the measurement solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDC13) deuterated methanol (CD3OD), the internal standard is tetramethylsilane (TMS), and the chemical shift is 10 -6 (ppm) is given as the unit.
[0046] MS was measured using an Agilent SQD (ESI) mass spectrometer (manufacturer: Agilent, model: 6110) or a Shimadzu SQD (ESI) mass spectrometer (manufacturer: Shimadzu, model: 2020).
[0047] HPLC determination was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfirc C18, 150×4.6 mm, 5 μm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18, 150×4.6 mm, 5 μm column).
[0048] The thin layer chromatography silica gel plate used was Qingdao Ocean GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) had a specification of 0.15mm-0.2mm, and the thin layer chromatography separation and purification product used a 0.4mm-0.5mm silica gel plate.
[0049] Column chromatography generally uses Qingdao Ocean 200-300 mesh silica gel as the carrier.
[0050] The known starting materials of the present invention can be synthesized by methods known in the art, such as Accela ChemBio Inc., Beijing Coupling Chemicals, etc.
[0051] Unless otherwise specified in the examples, the reactions were carried out under an argon atmosphere or a nitrogen atmosphere. The hydrogenation reaction was usually carried out by evacuating the air and filling it with hydrogen, and the operation was repeated three times.
[0052] Unless otherwise specified in the examples, the reaction temperature is room temperature, which ranges from 20°C to 30°C.
[0053] The reaction progress in the examples was monitored by thin layer chromatography (TLC), and the developing solvent systems used in the reaction were A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system, and the volume ratio of the solvents was adjusted according to the polarity of the compounds.
[0054] The eluent system for column chromatography and the developing solvent system for thin layer chromatography used for purifying compounds include A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine and acidic or alkaline reagents can also be added for adjustment.
[0055] Example 1: Preparation of the compound represented by formula I-1
[0056]
[0057] Synthesis route:
[0058]
[0059] Step 1: Synthesis of compound 1B
[0060] Compound 1A (5 g, 39.7 mmol) was dissolved in dichloromethane (100 ml), cooled to 0 to 5°C, and then 70% nitric acid (5 ml) was slowly added dropwise. The internal temperature was kept below 5°C during the addition. After the addition was completed, the temperature was raised to room temperature and the reaction was continued for one hour. TLC showed that the reaction was completed. The reaction solution was washed with water (50 mL×2), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude compound 1B (yellow oil, 4.48 g) with a yield of 66%, which was directly used in the next step without further purification.
[0061] Step 2: Synthesis of Compound 1C
[0062] The compound 1B (2.83 g, 16.5 mmol) obtained in the previous step was dissolved in DMF (25 ml), and then potassium carbonate (3.4 g, 25 mmol) and iodomethane (1.2 mL, 20 mmol) were added. After the addition, the mixture was stirred at room temperature overnight. TLC showed that the reaction was complete. The reaction solution was then poured into water, and a large amount of solid precipitated. The solid was filtered and the filter cake was washed with water several times to obtain compound 1C (2.76 g, yellow solid) with a yield of 90%.
[0063] Step 3: Synthesis of Compound 1D
[0064] Compound 1C (2.5 g, 13.5 mmol) obtained in the previous step was dissolved in DMF (25 ml) at room temperature, and then cesium carbonate (6.6 g, 20 mmol) and 1-ethyl-4-(4-piperidinyl)piperazine (2.47 g, 13.5 mmol) were added. The reaction temperature was heated to 80°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed, and then the reaction solution was poured into water and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL×2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 1D (4.0 g, yellow solid) with a yield of 85%.
[0065] MS m / z(ESI):349[M+1].
[0066] Step 4: Synthesis of Compound 1E
[0067] The compound 1D (4.0 g, 11.5 mmol) obtained in the previous step was dissolved in methanol (50 ml), and then 10% palladium on carbon (500 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 1E (3.42 g) with a yield of 93.5%, which was directly used in the next step without further purification.
[0068] MS m / z(ESI):319[M+1].
[0069] Step 5: Synthesis of Compound 1G
[0070] Compound 1F (10 g, 51 mmol) was dissolved in toluene (50 ml), and then benzophenone imine (10.9 g, 60 mml) was added, followed by cesium carbonate (32.6 g, 100 mmol), Pd2dba3 (2.3 g, 2.5 mmol) and xantphos (1.44 g, 2.5 mmol). After the addition, the mixture was replaced with nitrogen three times, and then the temperature was raised to 110°C under nitrogen protection for 3 hours. TLC showed that the reaction was completed, water was added, the organic layer was separated, and the aqueous phase was extracted with ethyl acetate (50 mL×2). The organic phases were combined, and then the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by concentration was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1-1:1) to obtain compound 1G (12.7 g, yellow solid) with a yield of 83%.
[0071] MS m / z(ESI):299[M+1]
[0072] Step 6: Synthesis of compound 1H
[0073] The intermediate 1G (12.5 g, 42 mmol) obtained in the previous step was dissolved in THF (200 ml), and concentrated hydrochloric acid (20 ml) was slowly added under stirring at room temperature, and then stirring was continued at room temperature for 2 hours. TLC showed that the reaction was completed. After the reaction was completed, the reaction solution was slowly added to a saturated sodium bicarbonate aqueous solution, and the internal temperature was protected to be less than 10°C. It was extracted with ethyl acetate (50 mL×2), the organic phases were combined, and then the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 1H (5.3 g, yellow solid) with a yield of 93%.
[0074] MS m / z(ESI):135[M+1].
[0075] Step 7: Synthesis of Compound 1I
[0076] The compound 1H (5 g, 37 mmol) obtained in the previous step was dissolved in DMF (50 ml), and sodium periodate (9.5 g, 44.4 mmol) was added at room temperature. After stirring for 10 minutes, iodine (11.3 g, 44.4 mmol) was added in batches. After the addition, the reaction was allowed to react for 2 hours. TLC showed that the reaction was complete. The reaction solution was then added to a saturated sodium thiosulfate solution and stirred until it was colorless. The obtained aqueous phase was extracted with ethyl acetate (50 mL×2), and the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 1I (6.18 g, yellow solid) with a yield of 64%.
[0077] MS m / z(ESI):261[M+1].
[0078] Step 8: Synthesis of Compound 1J
[0079] Compound 1I (6.1 g, 23.5 mmol) obtained in the previous step was added to DMF (100 ml), and then dimethylphosphine oxide (2.2 g, 28 mmol), potassium phosphate (10 g, 47 mmol), palladium acetate (515 mg, 2.3 mmol) and Xanthpos (1.33 g, 2.3 mmol) were added in sequence. After the addition was complete, the mixture was replaced with nitrogen three times. The mixture was reacted at 150 °C for 3 hours under nitrogen protection. After TLC showed that the reaction was completed, the mixture was cooled to room temperature, added to water, and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine ((50 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent: dichloromethane: methanol = 50:1-10:1) to obtain compound 1J (3.3 g, yellow solid) with a yield of 67%.
[0080] MS m / z(ESI):211[M+1].
[0081] Step 9: Synthesis of Compound 1K
[0082] Compound 1J (3.3 g, 15.6 mmol) obtained in the previous step was added to DMF (50 ml). After stirring and dissolving, 5-bromo-2,4-dichloropyrimidine (5.33 g, 23.4 mmol) and potassium carbonate (4.3 g, 31.2 mmol) were added in sequence, and then heated to 60°C and reacted for 4 hours. After TLC showed that the reaction was completed, the reaction solution was cooled to room temperature and poured into water. The mixture was extracted with ethyl acetate (50 mL×2). The organic phases were combined and washed with saturated brine (50 mL×2). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was filtered through a silica gel chromatography column (eluent: dichloromethane: methanol = 50:1-10:1) to obtain compound 1K (3.6 g, yellow solid) with a yield of 57.8%.
[0083] MS m / z(ESI):401[M+1].
[0084] Step 10: Synthesize the compound represented by formula I-1
[0085] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 1E (261 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-1. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-1 (7.5 mg, white solid).
[0086] MS m / z(ESI):697[M+1]
[0087] 1H NMR (400MHz, MeOD): 8.72(d,J=2.8Hz,1H,8.44(s,1H),8.14(s,1H),7.73(d,J=9.6Hz,1H),7.50(s,1H),6.73(s,1H),3.83(s,3H),3.15(d ,J=11.6Hz,2H),2.77-2.35(m,13H),2.18(s,3H),2.15(s,3H),2.05(s,3H),2.04-2.01(m,2H),1.71-1.67(m,2H),1.13(t,J=7.2Hz,3H).
[0088] Example 2: Preparation of the compound represented by formula I-2
[0089]
[0090] Synthesis route:
[0091]
[0092] Step 1: Synthesis of compound 2A
[0093] Compound 1C (2.5 g, 13.5 mmol) was dissolved in DMF (25 ml) at room temperature, and then cesium carbonate (6.6 g, 20 mmol) and tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (3.63 g, 13.5 mmol) were added. The reaction temperature was heated to 80°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed, and then the reaction solution was poured into water and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL×2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1-1:1) to obtain compound 2A (5.0 g, yellow solid) with a yield of 85.5%.
[0094] MS m / z(ESI):435[M+1].
[0095] Step 2: Synthesis of compound 2B
[0096] The compound 2A (5.0 g, 11.5 mmol) obtained in the previous step was dissolved in dichloromethane (50 ml) solution, and then TFA (10 ml) was added at room temperature. After the addition, stirring was continued at room temperature for 2 hours. TLC showed that the reaction was completed. The mixture was concentrated to dryness to obtain a crude compound 2B (4.5 g, brown oil), which was directly used in the next step without purification.
[0097] MS m / z(ESI):335[M+1].
[0098] Step 3: Synthesis of Compound 2C
[0099] Compound 2B (4.5 g) was dissolved in dichloromethane (DCM) (50 ml), cooled to 0-5°C in an ice-water bath, and then triethylamine (3.5 g, 34.5 mmol) was added, and then a DCM solution (5 ml) of methyl chloroformate (1.64 g, 17.3 mmol) was added dropwise. The internal temperature was kept below 5°C during the addition. After the addition was completed, the temperature was raised to room temperature and the reaction was carried out for 2 hours. TLC showed that the reaction was complete. The reaction solution was washed with water twice (15 ml×3), the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying and passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1-1:1) to obtain compound 2C (2.48 g, yellow solid). The two-step yield was 55%.
[0100] MS m / z(ESI):393[M+1].
[0101] Step 4: Synthesis of compound 2D
[0102] The compound 2C (2.4 g, 6.12 mmol) obtained in the previous step was dissolved in methanol (25 ml), and then 10% palladium on carbon (250 mg) was added. The hydrogen was replaced by a hydrogen balloon three times, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 2D (2.07 g) with a yield of 93.5%, which was directly used in the next step without further purification.
[0103] MS m / z(ESI):363[M+1].
[0104] Step 5: Synthesize the compound shown in formula I-2
[0105] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 2D (272 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-2. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-2 (5.5 mg, white solid).
[0106] MS m / z(ESI):630[M+1].
[0107] 1 H NMR(400MHz,MeOD):8.72(d,J=2.4Hz,1H),8.44(s,1H),8.17(s,1H),7.73( d,J=9.6Hz,1H),7.49(s,1H),6.73(s,1H),3.83(s,3H),3.70(s,3H),3.50(b rs,4H),3.15(d,J=11.6Hz,2H),2.71-2.63(m,6H),2.43-2.36(m,1H),2.18( s,3H),2.15(s,3H),2.05(s,3H),1.98(d,J=12.4Hz,2H),1.73-1.69(m,2H).
[0108] Example 3: Preparation of the compound represented by formula I-3
[0109]
[0110] Synthesis route:
[0111]
[0112] Step 1: Synthesis of compound 3A
[0113] The crude compound 2B (1.00 g, 3 mmol) was dissolved in DCM (10 ml), cooled to 0-5°C in an ice-water bath, and then triethylamine (910 mg, 9 mmol) was added, and then a solution of acetyl chloride (351 mg, 4.5 mmol) in DCM (5 ml) was added dropwise. The internal temperature was kept below 5°C during the addition. After the addition was completed, the temperature was raised to room temperature and the reaction was carried out for 2 hours. TLC showed that the reaction was complete. The reaction solution was washed with water twice (10 ml×2), the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying and passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 3A (959 mg, yellow solid) with a yield of 85%.
[0114] MS m / z(ESI):377[M+1].
[0115] Step 2: Synthesis of compound 3B
[0116] The compound 3A (950 mg, 2.53 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (100 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to give a crude compound 3B (830 mg) with a yield of 95%, which was used directly in the next step without further purification.
[0117] MS m / z(ESI):347[M+1].
[0118] Step 3: Synthesize the compound represented by formula I-3
[0119] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 3B (260, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-3. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-3 (7.3 mg, white solid).
[0120] MS m / z(ESI):711[M+1].
[0121] 1 H NMR(400MHz,MeOD):8.73(dd,J=2Hz,9.2Hz,1H),8.44(s,1H),8.17(s,1H), 7.72(d,J=9.6Hz,1H),7.50(s,1H),6.73(s,1H),3.83(s,3H),3.63-3.60(m, 4H),3.17-3.11(m,2H),2.73-2.65(m,6H),2.50-2.48(m,1H),2.18(s,3H),2 .15(s,3H),2.11(s,3H),2.02(s,3H),1.99-1.80(m,2H),1.78-1.68(m,2H).
[0122] Example 4: Preparation of the compound represented by formula I-4
[0123]
[0124] Synthesis route:
[0125]
[0126] Step 1: Synthesis of compound 4A
[0127] The crude compound 2B (1.00 g, 3 mmol) was dissolved in DCM (10 ml), cooled to 0-5°C in an ice-water bath, and then triethylamine (910 mg, 9 mmol) and N,N'-carbonyldiimidazole (CDI) (583 mg, 3.6 mmol) were added. After the addition was completed, the temperature was raised to room temperature for reaction for 2 hours. TLC showed that the reaction was complete. Then triethylamine (303 mg, 3 mmol) and methylamine hydrochloride (245 mg, 3.6 mmol) were added, and the reaction was continued at room temperature overnight. TLC showed that the reaction was complete. 30 ml of DCM was added, and the mixture was washed twice with water (15 ml×2). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying and passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain compound 4A (991 mg, yellow solid) with a yield of 84.5%.
[0128] MS m / z(ESI):392[M+1].
[0129] Step 2: Synthesis of compound 4B
[0130] The compound 4A (950 mg, 2.43 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 4B (829 mg) with a yield of 94.5%, which was directly used in the next step without further purification.
[0131] MS m / z(ESI):362[M+1].
[0132] Step 3: Synthesize the compound represented by formula I-4
[0133] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 4B (270 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-4. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-4 (7.1 mg, white solid).
[0134] MS m / z(ESI):726[M+1].
[0135] 1 H NMR(400MHz,MeOD):8.73(d,J=13.2Hz,1H),8.44(s,1H),8.17(s,1H),7.73 (d,J=9.6Hz,1H),7.49(s,1H),6.74(s,1H),3.83(s,3H),3.43-3.41(m,4H) ,3.16(d,J=12Hz,2H),2.73(s,3H),2.72-2.63(m,6H),2.45-2.38(m,1H),2 .18(s,3H),2.15(s,3H),2.06(s,3H),2.04-1.98(m,2H),1.73-1.70(m,2H).
[0136] Example 5: Preparation of the compound represented by formula I-5
[0137]
[0138] Synthesis route:
[0139]
[0140] Step 1: Synthesis of compound 5A
[0141] The crude compound 2B (1.00 g, 3 mmol) was dissolved in DCM (10 ml), cooled to 0-5°C in an ice-water bath, and then triethylamine (910 mg, 9 mmol) and MsCl (410 mg, 3.6 mmol) were added. After the addition was completed, the temperature was raised to room temperature and the reaction was carried out for 2 hours. TLC showed that the reaction was completed, and then 30 ml of DCM was added. The mixture was washed with water twice (15 ml×2), and the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was filtered through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain compound 5A (1.07 g, yellow solid) with a yield of 86.3%.
[0142] MS m / z(ESI):413[M+1].
[0143] Step 2: Synthesis of compound 5B
[0144] Compound 5A (1.0 g, 11.5 mmol) obtained in the previous step was dissolved in methanol (20 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 5B (0.89 g) with a yield of 95.5%, which was directly used in the next step without further purification.
[0145] MS m / z(ESI):383[M+1].
[0146] Step 3: Synthesize the compound represented by formula I-5
[0147] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 5B (287 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-5. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-5 (4.3 mg, white solid).
[0148] MS m / z(ESI):747[M+1].
[0149] 1 H NMR (400MHz, CDCl3): 11.33 (s, 1H), 8.87 (dd, J = 3.2Hz, 10Hz, 1H), 8.30 (s, 1H), 8. 23(s,1H),7.88(s,1H),7.79(d,J=10Hz,1H),7.30(s,1H),6.61(s,1H),3.85(s,3H ),3.28(brs,4H),3.17(d,J=10.8Hz,2H),2.80(s,6H),2.79-2.76(m,2H),2.68-2. 62(m,1H),2.19(s,3H),2.15(d,J=6Hz,6H),1.93-1.91(m,2H),1.74-1.62(m,2H).
[0150] Example 6: Preparation of the compound represented by formula I-6
[0151]
[0152] Synthesis route:
[0153]
[0154] Step 1: Synthesis of compound 6A
[0155] The crude compound 2B (1 g, 3 mmol) was dissolved in DMF (15 ml), and potassium carbonate (1.24 g, 9 mmol) and bromoethanol (562 mg, 4.5 mmol) were added in sequence. After the addition was completed, the temperature was raised to 60°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed. The reaction solution was poured into water (100 ml), extracted with ethyl acetate (50 ml × 3), the organic phases were combined, and washed twice with water (50 ml × 2), the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying and passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 6A (737 mg, yellow solid) with a yield of 65%.
[0156] MS m / z(ESI):379[M+1].
[0157] Step 2: Synthesis of compound 6B
[0158] The compound 6A (730 mg, 1.9 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through silica gel and washed with methanol. The filtrate was concentrated to give a crude compound 6B (625 mg) with a yield of 94.5%, which was used directly in the next step without further purification.
[0159] MS m / z(ESI):349[M+1].
[0160] Step 3: Synthesize the compound represented by formula I-6
[0161] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 6B (261 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1-10:1) to obtain a crude product of the compound represented by formula I-6. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase 10-100% acetonitrile (0.05% TFA) / water), flow rate 20mL / min, lasting 10 minutes, to obtain the target product compound represented by formula I-6 (7.5mg, white solid), MS m / z (ESI): 713[M+1].
[0162] 1H NMR (400MHz, MeOD): 8.72(d,J=9.6Hz,1H),8.44(s,1H),8.17(s,1H),7.73(d,J=8.8Hz,1H),7.49(s,1H),6.74(s,1H),3.83(s,3H),3. 71-3.67(m,2H),3.17-3.12(m,3H),2.72-2.52(m,12H),2.18(s,3H),,2.15(s,3H),2.06(s,3H),2.02-1.80(m,2H),1.73-1.64(m,2H).
[0163] Example 7: Preparation of the compound represented by formula I-7
[0164]
[0165] Synthesis route:
[0166]
[0167] Step 1: Synthesis of compound 7A
[0168] Compound 1C (10 g, 54 mmol) was dissolved in DMF (100 ml) at room temperature, and then cesium carbonate (17.6 g, 20 mmol) and 4-piperidone glycol acetal (11.6 g, 81 mmol) were added. The reaction temperature was heated to 80 ° C. The reaction was allowed to react for 4 hours. TLC showed that the reaction was completed. The reaction solution was then poured into water (500 ml), extracted with ethyl acetate (150 mL × 2), and the organic phases were combined. The organic phases were washed with saturated brine (150 mL × 2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1-1:1) to obtain compound 7A (13.9 g, yellow liquid) with a yield of 83.5%.
[0169] MS m / z(ESI):309[M+1].
[0170] Step 2: Synthesis of compound 7B
[0171] Compound 7A (13.5 g, 43.8 mmol) obtained in the previous step was added to water (500 ml), and then p-toluenesulfonic acid hydrate (8.33 g, 43.8 mmol) was added. After the addition, the temperature was raised to reflux and the reaction was carried out for 16 hours. After TLC showed that the reaction was completed, the mixture was cooled to room temperature, the pH value was adjusted to neutral with potassium carbonate, and then extracted with ethyl acetate (150 ml×3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was filtered through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 7B (8.9 g, yellow solid) with a yield of 77.2%.
[0172] MS m / z(ESI):265[M+1].
[0173] Step 3: Synthesis of Compound 7C
[0174] Compound 7B (1 g, 3.77 mol) was added to methanol (20 ml) at room temperature, and then acetic acid (0.2 ml) and N-methylhomopiperazine (644 mg, 5.65 mmol) were added. After stirring at room temperature for 2 hours, sodium cyanoborohydride (356 mg, 5.65 mmol) was added in batches. The reaction was continued to stir at room temperature overnight. TLC showed that the reaction was completed, and then the methanol was removed by spin drying. 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), and then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1-10:1) to obtain compound 7C (914 mg, yellow solid) with a yield of 67%.
[0175] MS m / z(ESI):363[M+1].
[0176] Step 4: Synthesis of compound 7D
[0177] The compound 7C (900 mg, 2.5 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced by a hydrogen balloon three times, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 7D (768 mg) with a yield of 92.5%, which was directly used in the next step without further purification.
[0178] MS m / z(ESI):333[M+1].
[0179] Step 5: Synthesize the compound represented by formula I-7
[0180] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 7D (250 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-7. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-7 (7.2 mg, white solid).
[0181] MS m / z(ESI):697[M+1].
[0182] 1 H NMR (400MHz, MeOD): 8.73(d,J=10Hz,1H),8.44(s,1H),8.17(s,1H),7.72(d,J=10Hz,1H),7.49(s,1H),6.73(s,1H),3.82(s,3H),3.16-2.1 3(m,2H),2.94-2.91(m,4H),2.74-2.59(m,7H),2.38(s,3H),2.18(s, 3H),2.15(s,3H),2.05(s,3H),1.93-1.86(m,4H),1.77-1.71(m,2H).
[0183] Example 8: Preparation of the compound represented by formula I-8
[0184]
[0185] Synthesis route:
[0186]
[0187] Step 1: Synthesis of compound 8A
[0188] Compound 7B (1 g, 3.77 mol) was added to methanol (20 ml) at room temperature, followed by acetic acid (0.2 ml) and thiomorpholine 1,1-dioxide (763 mg, 5.65 mmol). After stirring at room temperature for 2 hours, sodium cyanoborohydride (356 mg, 5.65 mmol) was added in batches. The mixture was stirred at room temperature overnight. TLC showed that the reaction was complete. The methanol was removed by spin drying, 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying. The residue was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50: 1-10: 1) to obtain compound 8A (881 mg, yellow solid). The yield was 61%, MS m / z (ESI): 384 [M+1].
[0189] Step 2: Synthesis of compound 8B
[0190] The compound 8A (800 mg, 2.1 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (500 mg) was added. The hydrogen was replaced by a hydrogen balloon three times, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 8B (696 mg) with a yield of 94.5%, which was directly used in the next step without further purification.
[0191] MS m / z(ESI):354[M+1].
[0192] Step 3: Synthesize the compound represented by formula I-8
[0193] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 8B (266 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1-10:1) to obtain a crude product of the compound represented by formula I-8. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-8 (7.6 mg, white solid).
[0194] MS m / z(ESI):718[M+1].
[0195] 1 H NMR (400MHz, DMSO-d6): 11.37(s,1H),8.67(d,J=10Hz,1H),8.53(s,1H),8.23(d,J=4Hz,1H),7.32(s,1H),6.74(s,1H), 3.77(s,3H),3.08(brs,7H),3.03(brs,4H),2.69-2.64(m,3H),2.08-2.05(m,9H),1.92-1.79(m,2H),1.68-1.63(m,2H).
[0196] Example 9: Preparation of the compound represented by formula I-9
[0197]
[0198] Synthesis route:
[0199]
[0200] Step 1: Synthesis of compound 9A
[0201] Compound 7B (1 g, 3.77 mol) was added to methanol (20 ml) at room temperature, and then acetic acid (0.2 ml) and morpholine (763 mg, 5.65 mmol) were added. After stirring at room temperature for 2 hours, sodium cyanoborohydride (356 mg, 5.65 mmol) was added in batches. The reaction was continued to stir at room temperature overnight. TLC showed that the reaction was completed. Then, the methanol was removed by spin drying, 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), and then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50: 1-10: 1) to obtain compound 9A (881 mg, yellow solid) with a yield of 61%.
[0202] MS m / z(ESI):336[M+1].
[0203] Step 2: Synthesis of compound 9B
[0204] The compound 9A (850 mg, 2.5 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to give a crude compound 9B (707 mg) with a yield of 92.5%, which was used directly in the next step without further purification.
[0205] MS m / z(ESI):306[M+1].
[0206] Step 3: Synthesize the compound represented by formula I-9
[0207] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 9B (230 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-9. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-9 (5.5 mg, white solid).
[0208] MS m / z(ESI):670[M+1].
[0209] 1 H NMR (400MHz, MeOD): 8.73(d,J=7.2Hz,1H),8.44(s,1H),8.17(s,1H),7.73(d,J=10Hz,1H),7.50(s,1H),6.73(s,1H),3.82(s,3H),3.75-3.72(m ,4H),3.15(d,J=12Hz,2H),2.74-2.65(m,6H),2.35-2.30(m,1H),2.18( s,3H),2.15(s,3H),2.05(s,3H),2.01-1.92(m,2H),1.69-1.66(m,2H).
[0210] Example 10: Preparation of the compound represented by formula I-10
[0211]
[0212] Synthesis route:
[0213]
[0214] Step 1: Synthesis of compound 10B
[0215] Compound 10A (2.3 g, 13.5 mmol) was dissolved in DMF (25 ml) at room temperature, and then cesium carbonate (6.6 g, 20 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (2.47 g, 13.5 mmol) were added. The reaction temperature was heated to 80°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed, and then the reaction solution was poured into water and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL×2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 10B (3.76 g, yellow solid) with a yield of 83.5%.
[0216] MS m / z(ESI):335[M+1].
[0217] Step 2: Synthesis of Compound 10C
[0218] The compound 10B (2.0 g, 6 mmol) obtained in the previous step was dissolved in methanol (20 ml), and then 10% palladium on carbon (400 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through silica gel and washed with methanol. The filtrate was concentrated to obtain a crude compound 10C (1.7 g) with a yield of 95.6%, which was directly used in the next step without further purification.
[0219] MS m / z(ESI):305[M+1].
[0220] Step 3: Synthesis of Compound 10E
[0221] Compound 1J (2.1 g, 10 mmol) obtained in the previous step was added to DMF (30 ml). After stirring and dissolving, 2,4,5-trichloropyrimidine (2.18 g, 12 mmol) and potassium carbonate (2.76 g, 20 mmol) were added in sequence. The mixture was heated to 60°C and reacted for 4 hours. After TLC showed that the reaction was completed, the mixture was cooled to room temperature and poured into water (150 ml). The mixture was extracted with ethyl acetate (50 mL × 2). The organic phases were combined and washed with saturated brine (50 mL × 2). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was filtered through a silica gel chromatography column (eluent: dichloromethane: methanol = 50:1-10:1) to obtain compound 10E (2.09 g, yellow solid) with a yield of 58.7%.
[0222] MS m / z(ESI):357[M+1].
[0223] Step 4: Synthesize the compound represented by formula I-10
[0224] The compound 10E (180 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 10C (228 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90°C for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-10. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-10 (7.2 mg, white solid).
[0225] MS m / z(ESI):625[M+1].
[0226] 1 H NMR (400MHz, MeOD): 8.93 (dd, J = 2Hz, 5.6Hz, 1H), 8.42 (s, 1H), 8.06 (s, 1H), 7. 75(d,J=10Hz,1H),7.52(d,J=8.8Hz,1H),6.69(d,J=2.4Hz,1H),6.52(dd,J=2 .4Hz,8.8Hz,1H),3.84(s,3H),3.75(d,J=12.4Hz,2H),2.76-2.37(m,11H),2. 29(s,3H),2.18(s,3H),2.14(s,3H),2.04(d,J=12Hz,2H),1.71-1.65(m,2H).
[0227] Example 11: Preparation of the compound represented by formula I-11
[0228]
[0229] Synthesis route:
[0230]
[0231] Step 1: Synthesis of compound 11A
[0232] Compound 1C (2.5 g, 13.5 mmol) was dissolved in DMF (25 ml) at room temperature, and then cesium carbonate (6.6 g, 20 mmol) and NBoc piperazine (2.51 g, 13.5 mmol) were added. The reaction temperature was heated to 80°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed, and then the reaction solution was poured into water (100 ml), extracted with ethyl acetate (50 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (50 mL×2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 11A (4.06 g, yellow solid) with a yield of 85.6%.
[0233] MS m / z(ESI):352[M+1].
[0234] Step 2: Synthesis of compound 11B
[0235] The compound 11A (4.0 g, 11.4 mmol) obtained in the previous step was dissolved in dichloromethane solution (50 ml), and then TFA (10 ml) was added at room temperature. After the addition, stirring was continued at room temperature for 2 hours. TLC showed that the reaction was completed. The mixture was concentrated to dryness to obtain a crude compound 11B (3.8 g, brown oil), which was directly used in the next step without purification.
[0236] Step 3: Synthesis of Compound 11C
[0237] The crude compound 11B (1.9 g) obtained in the previous step was added to methanol (20 ml) at room temperature, and then 3-oxetanone (792 mg, 11 mmol) was added. After stirring at room temperature for 2 hours, sodium cyanoborohydride (704 mg, 11 mmol) was added in batches. The reaction was continued to stir at room temperature overnight. TLC showed that the reaction was completed, and then the methanol was removed by spin drying. 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml×3). The organic phases were combined, washed with saturated brine (20 mL×2), and then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1-10:1) to obtain compound 11C (717 mg, yellow solid). The two-step yield was 41%.
[0238] MS m / z(ESI):308[M+1].
[0239] Step 4: Synthesis of compound 11D
[0240] The compound 11C (700 mg, 2.28 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (150 mg) was added. The hydrogen was replaced by a hydrogen balloon three times, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 11D (597 mg) with a yield of 94.2%, which was directly used in the next step without further purification.
[0241] MS m / z(ESI):278[M+1].
[0242] Step 5: Synthesize the compound represented by formula I-11
[0243] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 11D (208 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90°C for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1-10:1) to obtain a crude product of the compound represented by formula I-11. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-11 (6.1 mg, white solid).
[0244] MS m / z(ESI):642[M+1].
[0245] 1 H NMR(400MHz,MeOD):8.72(dd,J=2.8Hz,10Hz,1H),8.44(s,1H),8.18(s,1H),7.73(d,J=5.2Hz,1H),7.54(s,1H),6.77(s,1H),4.87-4.7 4(m,2H),4.67-4.64(m,2H),3.85(s,3H),3.62-3.58(m,1H),2.97-.295(m,4H),2.55(brs,4H),2.18(s,3H),2.14(s,3H),2.04(s,3H).
[0246] Example 12: Preparation of the compound represented by formula I-12
[0247]
[0248] Synthesis route:
[0249]
[0250] Step 1: Synthesis of compound 12B
[0251] Compound 12A (11.5 g, 53 mmol) was dissolved in a mixed solvent of acetonitrile (150 ml) and water (30 ml), and then formaldehyde aqueous solution (11 mL, 160 mmol) was added. After stirring at room temperature for 2 hours, sodium acetate borohydride (22.5 g, 110 mmol) was added in batches. After the addition, the mixture was reacted at room temperature overnight. TLC showed that the reaction was complete. Then, saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH value to pH = 8, and then dichloromethane (500 ml) and methanol (50 ml) were added to dilute the reaction solution. The reaction solution was washed with saturated sodium carbonate aqueous solution (100 mL×2), the organic phase was separated, dried over anhydrous sodium sulfate, and spin-dried to obtain product 12B (11.9 g, white solid), which was directly used in the next step without purification with a yield of 98%.
[0252] MS m / z(ESI):231[M+1].
[0253] Step 2: Synthesis of Compound 12C
[0254] The compound 2B (11 g, 47.8 mmol) obtained in the previous step was dissolved in dichloromethane solution (150 ml), and then TFA (30 ml) was added at room temperature. After the addition, stirring was continued at room temperature for 2 hours. TLC showed that the reaction was completed. The mixture was concentrated to dryness to obtain a crude compound 12C (9.2 g, brown oil), which was directly used in the next step without purification.
[0255] MS m / z(ESI):131[M+1].
[0256] Step 3: Synthesis of Compound 12D
[0257] Compound 1C (2.5 g, 13.5 mmol) was dissolved in DMF (25 ml) at room temperature, and then cesium carbonate (6.6 g, 20 mmol) and compound 12C (1.75 g, 13.5 mmol) were added. The reaction temperature was heated to 80°C and the reaction was carried out for 4 hours. TLC showed that the reaction was completed, and then the reaction solution was poured into water and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL×2), and then dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel chromatography column (eluent petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 12D (3.4 g, yellow solid) with a yield of 85.7%.
[0258] MS m / z(ESI):296[M+1].
[0259] Step 4: Synthesis of compound 12E
[0260] The compound 12D (1.0 g, 3.39 mmol) obtained in the previous step was dissolved in methanol (20 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 12E (858 mg) with a yield of 95.2%, which was directly used in the next step without further purification.
[0261] MS m / z(ESI):266[M+1].
[0262] Step 5: Synthesize the compound represented by formula I-12
[0263] Compound 1K (200 mg, 0.5 mmol) was dissolved in n-butanol (5 ml), and compound 12E (200 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90°C for four days. TLC showed that the reaction was completed. The solution was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The solution was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude compound compound I-12. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-12 (5.5 mg, white solid).
[0264] MS m / z(ESI):630[M+1].
[0265] 1H NMR(400MHz,MeOD):8.71(dd,J=2.8Hz,9.6Hz,1H),8.44(s,1H),8.18(s,1H), 7.76(d,J=9.6Hz,1H),7.54(s,1H),6.75(s,1H),3.84(s,3H),3.83-3.80(m,1H ),3.63-3.58(m,1H),3.16(d,J=11.6Hz,1H),2.99-2.85(m,3H),2.69-2.64(m, 1H),2.58-2.56(m,1H),2.43(brs,4H),2.18(s,3H),2.15(s,3H),2.03(s,3H).
[0266] Example 13: Preparation of the compound represented by formula I-13
[0267]
[0268] Synthesis route:
[0269]
[0270] Step 1: Synthesis of compound 13A
[0271] Compound 7B (1 g, 3.77 mol) was added to methanol (20 ml) at room temperature, and then acetic acid (0.2 ml) and compound 12C (734 mg, 5.65 mmol) were added. After stirring at room temperature for 2 hours, sodium cyanoborohydride (356 mg, 5.65 mmol) was added in batches. The reaction was continued to stir at room temperature overnight. TLC showed that the reaction was completed, and then the methanol was removed by spin drying. 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), and then dried over anhydrous sodium sulfate, filtered, and the residue was concentrated by spin drying. It was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50: 1-10: 1) to obtain compound 13A (892 mg, yellow solid) with a yield of 62.6%.
[0272] MS m / z(ESI):379[M+1].
[0273] Step 2: Synthesis of compound 13B
[0274] The compound 13A (800 mg, 2.12 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 13B (683 mg) with a yield of 92.7%, which was directly used in the next step without further purification.
[0275] MS m / z(ESI):349[M+1].
[0276] Step 3: Synthesize the compound represented by formula I-13
[0277] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 13B (261 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90°C for four days. TLC showed that the reaction was completed. The mixture was spin-dried and added to an aqueous sodium bicarbonate solution (30 ml). The mixture was extracted with dichloromethane (10 mL×2). The organic phases were combined and washed with saturated brine (10 mL×2). The organic phases were then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-13. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-13 (5.4 mg, white solid).
[0278] MS m / z(ESI):713[M+1].
[0279] 1H NMR(400MHz,MeOD):8.73(dd,J=2.0Hz,8.8Hz,1H),8.44(s,1H),8.16(s,1H),7.73(d,J=10.4Hz ,1H),7.50(s,1H),6.74(s,1H),3.85(s,3H),3.76-3.72(m,1H),3.57-3.53(m,1H),3.17-3.14(m ,3H),2.99-2.97(m,1H),2.88-2.86(m,1H),2.72-2.66(m,2H),2.42-2.37(m,2H),2.36(s,3H), 2.23-2.20(m,3H),2.18(s,3H),2.14(s,3H),2.05(s,3H),2.04-2.01(m,2H),1.72-1.69(m,2H).
[0280] Example 14: Preparation of the compound represented by formula I-14
[0281]
[0282] Synthesis route:
[0283]
[0284] Step 1: Synthesis of compound 14A
[0285] Compound 7B (1 g, 3.77 mol) was added to methanol (20 ml) at room temperature, and then acetic acid (0.2 ml) and N-methylpiperazine (565 mg, 5.65 mmol) were added. After stirring at room temperature for 2 hours, sodium cyanoborohydride (356 mg, 5.65 mmol) was added in batches. The reaction was continued to stir at room temperature overnight. TLC showed that the reaction was completed, and then the methanol was removed by spin drying. 100 ml of water was added, and the mixture was extracted with dichloromethane (25 ml × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), and then dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50: 1-10: 1) to obtain compound 14A (827 mg, yellow solid) with a yield of 63%.
[0286] MS m / z(ESI):349[M+1].
[0287] Step 2: Synthesis of compound 14B
[0288] The compound 14A (800 mg, 2.3 mmol) obtained in the previous step was dissolved in methanol (10 ml), and then 10% palladium on carbon (200 mg) was added. The hydrogen was replaced three times with a hydrogen balloon, and then the hydrogen atmosphere was maintained and stirred at room temperature overnight. TLC showed that the reaction was completed. The mixture was filtered through siliceous earth and washed with methanol. The filtrate was concentrated to obtain a crude compound 14B (669 mg) with a yield of 91.5%, which was directly used in the next step without further purification.
[0289] MS m / z(ESI):319[M+1].
[0290] Step 3: Synthesize the compound represented by formula I-14
[0291] The compound 1K (200 mg, 0.5 mmol) obtained in the previous step was dissolved in n-butanol (5 ml), and compound 14B (238 mg, 0.75 mmol) and concentrated hydrochloric acid (0.5 ml) were added in sequence. The reaction solution was reacted at 90° C. for four days. TLC showed that the reaction was completed. The mixture was spin-dried, added to an aqueous sodium bicarbonate solution (30 ml), extracted with dichloromethane (10 mL×2), and the organic phases were combined. The organic phases were washed with saturated brine (10 mL×2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the residue obtained by spin-drying and concentration was passed through a silica gel chromatography column (eluent dichloromethane: methanol = 50:1 to 10:1) to obtain a crude product of the compound represented by formula I-14. The crude product was purified by reverse phase C18 preparative column YMC ODSA 30x 100mm (mobile phase: 10-100% acetonitrile (0.05% TFA) / water) at a flow rate of 20 mL / min for 10 minutes to obtain the target product, compound represented by formula I-14 (7.7 mg, white solid).
[0292] MS m / z(ESI):683[M+1].
[0293] 1 H NMR (400MHz, MeOD): 8.72(d,J=9.6Hz,1H),8.44(s,1H),8.16(s,1H),7.73(d,J=10.4Hz,1H),7.50(s,1H),6.73(s,1H),3.83(s,3H),3.15(dJ =12Hz,2H),2.75-2.66(m,10H),2.41-2.35(m,1H),2.32(s,3H),2.18( s,3H),2.14(s,3H),2.05(s,3H),2.04-2.01(m,2H),1.71-1.67(m,2H).
[0294] Effect Example 1: Cell Anti-Proliferation Experiment
[0295] (1) Experimental materials:
[0296] RPMI1640, glutamine, interleukin-3, and trypsin were purchased from Life Technology.
[0297] Fetal bovine serum and double-antibody were purchased from Hyclone.
[0298] Blasticidin was purchased from Merck.
[0299] Phosphate buffered saline was purchased from Corning.
[0300] CellTiter-Glo kit was purchased from Promega.
[0301] H1975 cells were purchased from ATCC.
[0302] Ba / F3 cells were purchased from Riken.
[0303] Ba / F3(EGFRΔ19del / T790M) cells and Ba / F3(EGFRΔ19del / T790M / C797S) cells were constructed by WuXi.
[0304] H1975 cell culture medium: 88% RPMI 1640, 10% fetal bovine serum, 1% glutamine, 1% double antibody.
[0305] Ba / F3 cell culture medium: 88% RPMI 1640, 10% fetal bovine serum, 10 ng / mL interleukin 3, 1% glutamine, 1% double antibody.
[0306] Ba / F3 (EGFRΔ19del / T790M) cell and Ba / F3 (EGFRΔ19del / T790M / C797S) cell culture medium: 87.9% RPMI 1640, 10% fetal bovine serum, 0.1% blasticidin, 1% glutamine, and 1% double antibody.
[0307] Experimental board: 781091 (Greiner)
[0308] Plate reader: Envision (PerkinElmer)
[0309] (2) Experimental methods:
[0310] Experimental method (H1975 cells): Digest and separate the cells in the T75 culture flask, resuspend them in culture medium, count them, and adjust the cell concentration to 2.0×10 4cells / mL, 100 μL phosphate buffer was added to the outer wells of the 384-well plate, 50 μL cell suspension was added to the other wells, and the mixture was allowed to stand at room temperature for 15 min, and then incubated in a 37°C 5% CO2 incubator for 24 h; the test compound was diluted 3-fold with DMSO at 10 points on ECHO, and 250 nL of the compound was transferred to the 384-well plate, respectively, with a final concentration of 5-0.00025 μM, 250 nL DMSO was transferred to the positive control and negative control, centrifuged at 1000 rpm for 15 s, and incubated in a 37°C 5% CO2 incubator for 72 h; 25 uL CellTiter-Glo was added to each well of the 384-well plate, centrifuged at 1000 rpm for 15 s, and shaken at room temperature for 15 min, and then read using Envision.
[0311] Experimental method (Ba / F3 cells, Ba / F3 (EGFRΔ19del / T790M) cells and Ba / F3 (EGFRΔ19del / T790M / C797S) cells): The test compound was diluted 3-fold with DMSO on ECHO plate at 10 points, and 250 nL of the compound was transferred to 384-well plates, with a final concentration of 5-0.00025 μM. 250 nL of DMSO was transferred to the positive control and negative control. The cells in the T75 culture flask were pipetted and counted, and the cell concentration was adjusted to 4×10 4 cells / mL, add 100 μL phosphate buffer to the outer wells of the 384-well plate, add 50 μL cell suspension to the other wells, let it stand at room temperature for 15 minutes, and then incubate it in a 37°C 5% CO2 incubator for 72 hours; add 25 μL CellTiter-Glo to each well of the 384-well plate, centrifuge at 1000 rpm for 15 seconds, shake at room temperature for 15 minutes, and read with Envision.
[0312] (3) Data analysis:
[0313] The readings were converted into inhibition rate (%) by the following formula: (Sample value-HC) / (LC-HC)*100. IC was determined by parameter curve fitting (XL-fit software). 50 data.
[0314] (4) Test results:
[0315] The cell activity inhibition IC of the compounds of the present invention against EGFRBa / F3 (Δ19del / T790M) 50 , H1975 cell activity inhibition IC 50 , EGFR Ba / F3(Δ19del / T 790M / C797S) cell activity inhibition IC 50, Ba / F3 parent cell activity inhibition IC 50 The data are shown in Table 1 below.
[0316] Among them, IC 50 Compounds between 1 and 100 nm are marked with +++, IC 50 Compounds between 100-1000nm are marked with ++, IC 50 Compounds larger than 1000 nm are marked with +.
[0317] Table 1: Cellular antiproliferative activity data of the compounds of the present invention (IC 50 )
[0318]
[0319]
[0320] From the experimental results in Table 1 we can see that:
[0321] (1) Most of the compounds of the present invention have a very good inhibitory effect on EGFR Ba / F3 (Δ19del / T790M / C797S) triple-mutated cells, and the cell anti-proliferation activity of some compounds is below 100 nm.
[0322] (2) EGFR Ba / F3 (Δ19del / T790M) is a cell model of EGFR double mutation and the main target of the third-generation EGFR TKIs. It mainly acts on the secondary mutation T790M that occurs in the ATP receptor part and produces resistance. Through testing, we found that most of the compounds of the present invention have a good cell anti-proliferation effect on the double mutation of EGFRBa / F3 (A19del / T790M), indicating that the compounds of the present invention have a dual inhibitory effect on the triple mutation and double mutation of EGFRBa / F3.
[0323] (3) The cell antiproliferation activity test of Ba / F3 parent and H1975 (EGFRWT) is a test for normal cells, which mainly determines the selective effect of the compound on normal cells. As can be seen from Table 1, the compound of the present invention has a very good inhibitory effect on triple mutations and double mutations, but a weak inhibitory effect on normal cells, indicating that the compound of the present invention has very good cell selectivity, weak toxicity, and has a very good anti-tumor application prospect.
[0324] Effect Example 2: Kinase Inhibition Activity Experiment
[0325] (1) Experimental materials:
[0326] EGFR T790M / C797S / L858R enzyme was purchased from Signalchem.
[0327] DTT and double distilled water were purchased from Life Technology.
[0328] Magnesium chloride was purchased from Fluka.
[0329] ATP was purchased from Sigma.
[0330] HTRF KinEASE-TK Kit was purchased from Cisbio.
[0331] Reaction buffer: 1X enzymatic buffer, 5mM magnesium chloride, 1mM DTT, double distilled water.
[0332] Experimental board: 6007299 (PerkinElmer)
[0333] Plate reader: Envision (PerkinElmer)
[0334] (2) Experimental methods:
[0335] The test compound was diluted 3-fold with DMSO at 11 points on ECHO, and 100 nL of the compound was transferred to a 384-well plate with a final concentration of 0.5-0.0000085 μM. 100 nL of MSK-1403 was transferred to the positive control with a final concentration of 1 μM, and 100 nL of DMSO was transferred to the negative control. A mixture of 1 nM EGFR T790M / C797S / L858R enzyme and 2 μM TKSubstrate-biotin was prepared with reaction buffer, and 5 μL was added to each well, shaken at room temperature for 15 s, centrifuged at 1000 rpm for 15 s, and incubated at 23°C for 15 min. 20 μM ATP was prepared with reaction buffer, and 5 μL was added to each well, shaken at room temperature for 15 s, centrifuged at 1000 rpm for 15 s, and incubated at 23°C for 60 min. 125 nM Streptavidin-XL665 and 1 / 2X TKAntibody-Cryptate mixture was added, and 10 μL was added to each well, shaken at room temperature for 15 seconds, centrifuged at 1000 rpm for 15 seconds, incubated at 23°C for 60 minutes, and read with Envision.
[0336] (3) Data analysis:
[0337] The readings were converted into inhibition rate (%) by the following formula: (Sample value-HC) / (LC-HC)×100%. IC was determined by parameter curve fitting (XL-fit software).50 data.
[0338] (4) Test results:
[0339] IC values of the EGFR (T790M / C797S / L858R) and EGFR (d746-750 / T790M / C797S) inhibitory activities of the compounds of the present invention 50 The data are shown in Table 2 below.
[0340] Among them, IC 50 Compounds between 0.1-10 nm are marked with +++, IC 50 Compounds between 10-100 nm are marked with ++, IC 50 Compounds larger than 100 nm are marked with +.
[0341] Table 2: Kinase inhibition data (IC 50 )
[0342]
[0343]
[0344] Results: As can be seen from Table 2, most of the compounds of the present invention have a very good inhibitory effect on the EGFR-C797S gene mutant kinase, and the enzyme activity of most compounds is less than 10nm, and some compounds are even less than 1nM, which has very good application prospects.
[0345] Effect Example 3: Drug Metabolism Experiment
[0346] 1. The compound I-14 of the present invention prepared in the above example was prepared into a 0.3 mg / mL clear solution (2% DMSO + 30% PEG 300 + 2% Tween 80 + 66% H2O) for oral administration and a 0.2 mg / mL clear solution (2% DMSO + 30% PEG 300 + 2% Tween 80 + 66% H2O) for intravenous administration.
[0347] 2. Male CD-1 mice, 3 mice in each group, weighing 27-28 g, provided by Shanghai Slake Experimental Animal Co., Ltd. The mice were given a 2-4 day environmental adaptation period before the experiment, fasted for 8-12 hours before administration, given water 2 hours after administration, and fed 4 hours after administration.
[0348] 3. After the mice were fasted but allowed to drink water freely for 12 hours, blank plasma was collected at time 0;
[0349] 4. Take the mice prepared in step 1) and administer 3 mg / kg of the test compound orally (PO); or 1 mg / kg of the test compound intravenously (IV);
[0350] 5. 5min, 15min, 30min, 1h, 2h, 4h, 8h, 10h, 24h after oral administration, continuously draw blood from the venous plexus of the fundus and place it in an EP tube with heparin. Centrifuge at 8000rpm / min for 5min and collect the upper plasma, freeze it at -20℃, and wait for LC-MS / MS analysis.
[0351] 6. Based on the blood drug concentration-time data obtained in step 3, the pharmacokinetic parameters were calculated using WinNonlin software. The specific data are shown in Table 3.
[0352] Table 3 - Pharmacokinetic data of the compounds of the present invention
[0353]
[0354] The pharmacokinetic experimental data are shown in Table 3. The results show that after oral or intravenous administration of the compounds represented by formula I-9 and I-14 of the present invention to mice, there are very high exposure amounts and very good half-life, area under the curve and bioavailability in animal plasma, good drugability, and good clinical application prospects.
[0355] Effect Example 4: Drug Metabolism Experiment
[0356] Experimental methods:
[0357] 1. In vivo efficacy experiments were performed on BALB / c nude mice implanted subcutaneously with Ba / F3 (Δ19del / T790M / C797S) derived xenografts (CDX). BALB / c nude mice, female, 6-8 weeks old, weighing approximately 18-22 grams, were housed in an SPF-grade environment, with each cage individually ventilated (5 mice per cage). All cages, bedding and water were disinfected before use. All animals had free access to standard certified commercial laboratory diets. A total of 48 mice purchased from Beijing Weitong Lihua were used for the study. Each mouse was implanted with cells subcutaneously in the right flank for tumor growth. The experiment was started when the average tumor volume reached approximately 150-200 cubic millimeters. The test compounds were administered orally daily, including compound Birgatinib (15 mg / kg), compound I-9 (150 mg 10 / kg) and compound I-14 (100 mg / kg), for 14 consecutive days.
[0358] 2. Tumor volume was measured twice a week using a two-dimensional caliper. The volume was measured in cubic millimeters and calculated using the following formula: V = 0.5a × b 2, where a and b are the long diameter and short diameter of the tumor, respectively. The antitumor efficacy is determined by dividing the average tumor volume increase of animals treated with the compound by the average tumor volume increase of untreated animals. TGI (the tumor inhibition value) is used to evaluate the inhibitory effect of the test drug on tumor growth in vivo, and the calculation company is: TGI (100%) = [(1-(average tumor volume at the end of the dosing group-average tumor volume at the beginning of the dosing of the group) / (average tumor volume at the end of the solvent control group-average tumor volume at the beginning of the solvent control group)] * 100%. The TGI of the compound Birgatinib (15 mg / kg) group was 8.6%, the TGI of the compound I-9 (150 mg / kg) group was 108%, and the TGI of the compound I-14 (100 mg / kg) group was 108%.
[0359] Experimental results: See Table 4.
[0360] Table 4
[0361]
[0362] In a mouse Ba / F3 (Δ19del / T790M / C797S) derived xenograft (CDX) subcutaneous transplant tumor model, the compound of the present invention has a significant inhibitory effect on tumor growth and has the effect of shrinking tumors, showing good anti-tumor efficacy.
[0363] In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. The specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. Those of ordinary skill in the art may make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention without departing from the principles and purpose of the present invention.
Claims
1. A compound, characterized in that Including a compound as shown in Formula I, or a pharmaceutically acceptable salt thereof; the compound as shown in Formula I is any of the following compounds: 。 2. A pharmaceutical composition comprising an effective dose of the compound of formula I as claimed in claim 1, and at least one pharmaceutical excipient.
3. Use of the compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or the pharmaceutical composition according to claim 2 in the preparation of an EGFR T790M / C797S inhibitor drug.
4. Use of the compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 2 in the preparation of a drug for treating and / or preventing a disease caused by the abnormal EGFR T790M / C797S mutation.
5. Use of the compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 2 in the preparation of a drug for treating and / or preventing cancer.
6. The use according to claim 5, characterized in that The cancers include lung cancer, glioma, kidney cancer, prostate cancer, pancreatic cancer, and breast cancer.
